About
Altris AI is a specialized artificial intelligence platform designed for eye care professionals and clinical researchers who rely on Optical Coherence Tomography (OCT) imaging. Founded in 2017, Altris AI automates the analysis of OCT scans to surface clinically meaningful insights faster and more consistently than manual review. The platform is built for three primary audiences: optometrists seeking to reduce over-referral and streamline workflows, ophthalmologists needing decision support for complex retinal cases, and pharmaceutical companies running clinical trials that require rapid, objective patient screening and treatment monitoring. Key capabilities include detection and measurement of 70+ retinal biomarkers and pathologies such as Geographic Atrophy (GA), wet and dry AMD, diabetic retinopathy, glaucoma, and fluid accumulation. Altris AI generates quantitative output including maps, graphs, and percentage-based insights, enabling objective longitudinal tracking across patient visits. A standout feature is its vendor-neutral compatibility—supporting OCT scans from 9 different manufacturers—making it practical for multi-device clinics and multi-center studies. For research and pharma teams, the tool accelerates patient enrollment by automatically filtering candidates by specific biomarkers and significantly reduces screen failure rates in clinical trials. The platform is accessible via an online interface, making it easy to integrate into existing clinical workflows. Altris AI is trusted by over 500 eye care businesses globally, including academic research institutions like the University of Helsinki and clinical research centers.
Key Features
- 70+ Retinal Biomarker Detection: Automatically identifies over 70 retinal biomarkers and pathologies including glaucoma, wet/dry AMD, geographic atrophy, diabetic retinopathy, and fluid accumulation.
- Quantitative OCT Analysis: Generates objective, data-driven insights such as maps, graphs, and percentage-based measurements to support clinical decisions and reduce reliance on manual interpretation.
- Vendor-Neutral Compatibility: Supports OCT scan uploads from 9 different OCT device manufacturers, enabling seamless use across diverse clinical and research environments.
- Clinical Trial Acceleration: Automates patient screening by biomarker criteria, significantly reducing screen failure rates and speeding up enrollment in pharmaceutical clinical trials.
- Longitudinal Analysis: Tracks patient data and biomarker changes over time to identify trends, monitor treatment outcomes, and support long-term research studies.
Use Cases
- Optometrists using AI-generated objective data to decide when to refer patients, reducing unnecessary over-referrals.
- Ophthalmologists monitoring macular degeneration and glaucoma patients with automated longitudinal biomarker tracking.
- Pharmaceutical companies screening and enrolling clinical trial participants faster by automatically filtering OCT scans for specific biomarkers.
- Research institutions analyzing tens of thousands of OCT scans to generate clinical insights and accelerate study timelines.
- Multi-center clinical studies requiring consistent, reproducible OCT interpretation across different sites and device types.
Pros
- Broad Pathology Coverage: Detecting 70+ biomarkers and retinal conditions in a single platform covers the full spectrum of common and complex eye diseases, reducing the need for multiple tools.
- Vendor-Neutral Device Support: Compatibility with 9 OCT manufacturers makes it highly versatile for clinics and multi-center research studies that use different imaging hardware.
- Proven Research-Grade Performance: Trusted by institutions like the University of Helsinki for large-scale studies (40K+ scans), demonstrating reliability for serious clinical and research applications.
- Reduces Manual Workload: Automatically highlights pathological scans and filters healthy ones, saving significant time for busy clinicians and research teams.
Cons
- Narrow Domain Specialization: The platform is exclusively focused on ophthalmic OCT imaging, making it unsuitable for any other medical imaging or clinical use case.
- Pricing Not Publicly Disclosed: Subscription costs are not listed publicly, requiring direct contact or a trial to understand pricing, which may slow adoption for budget-sensitive practices.
- Requires OCT Scan Input: Altris AI depends entirely on having access to OCT scan data; without compatible imaging equipment, the platform cannot be used.
Frequently Asked Questions
What is Altris AI?
Altris AI is an AI-powered decision support platform for OCT scan analysis. It automatically detects over 70 retinal biomarkers and pathologies to assist ophthalmologists, optometrists, and clinical researchers in making faster, more accurate clinical decisions.
Who is Altris AI designed for?
Altris AI serves three primary user groups: optometrists looking to reduce over-referrals, ophthalmologists needing objective decision support for complex retinal cases, and pharmaceutical or research teams running clinical trials involving retinal conditions.
Does Altris AI work with my existing OCT device?
Yes. Altris AI is vendor-neutral and supports OCT scans from 9 different manufacturers, making it compatible with most clinical and research imaging setups.
What retinal conditions can Altris AI detect?
Altris AI can detect and analyze over 70 retinal biomarkers and pathologies, including geographic atrophy (GA), wet and dry AMD, diabetic retinopathy, glaucoma, and various forms of retinal fluid.
Is there a free trial available?
Yes, Altris AI offers a 2-week free trial that does not require scheduling a call. You can start a trial directly from their website to evaluate the platform's clinical and commercial benefits.
